Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jenny Fröhlich"'
Autor:
Luke Stephen Tain, Robert Sehlke, Ralf Leslie Meilenbrock, Thomas Leech, Jonathan Paulitz, Manopriya Chokkalingam, Nagarjuna Nagaraj, Sebastian Grönke, Jenny Fröhlich, Ilian Atanassov, Matthias Mann, Andreas Beyer, Linda Partridge
Publikováno v:
eLife, Vol 10 (2021)
Reduced activity of the insulin/IGF signalling network increases health during ageing in multiple species. Diverse and tissue-specific mechanisms drive the health improvement. Here, we performed tissue-specific transcriptional and proteomic profiling
Externí odkaz:
https://doaj.org/article/f2129355d6fb4c9d8a2b6efe54ca2e46
Autor:
Jennifer C. Regan, Yu-Xuan Lu, Enric Ureña, Ralf L. Meilenbrock, James H. Catterson, Disna Kißler, Jenny Fröhlich, Emilie Funk, Linda Partridge
Publikováno v:
Regan, J C, Lu, Y X, Ureña, E, Meilenbrock, R L, Catterson, J H, Kißler, D, Fröhlich, J, Funk, E & Partridge, L 2022, ' Sexual identity of enterocytes regulates autophagy to determine intestinal health, lifespan and responses to rapamycin ', Nature Aging, vol. 2, no. 12, pp. 1145-1158 . https://doi.org/10.1038/s43587-022-00308-7
Nature Aging
Nature aging
Nature Aging
Nature aging
Pharmacological attenuation of mTOR presents a promising route for delay of age-related disease. Here we show that treatment of Drosophila with the mTOR inhibitor rapamycin extends lifespan in females, but not in males. Female-specific, age-related g
Autor:
Paula Juricic, Yu-Xuan Lu, Thomas Leech, Lisa F. Drews, Jonathan Paulitz, Jiongming Lu, Tobias Nespital, Sina Azami, Jennifer C. Regan, Emilie Funk, Jenny Fröhlich, Sebastian Grönke, Linda Partridge
The licensed drug rapamycin has potential to be repurposed for geroprotection. A key challenge is to avoid adverse side-effects from continuous dosing regimes. Here we show a profound memory effect of brief, early rapamycin treatment of adults, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::453c437a573e21ae683f8624dcbc6785
https://doi.org/10.1101/2022.04.20.488884
https://doi.org/10.1101/2022.04.20.488884
Autor:
Jonathan Paulitz, Luke S Tain, Linda Partridge, Sebastian Grönke, Andreas Beyer, Ralf Leslie Meilenbrock, Jenny Fröhlich, Manopriya Chokkalingam, Matthias Mann, Robert Sehlke, Nagarjuna Nagaraj, Thomas Leech, Ilian Atanassov
Publikováno v:
Elife
eLife
eLife, Vol 10 (2021)
eLife
eLife, Vol 10 (2021)
Reduced activity of the insulin/IGF signalling network increases health during ageing in multiple species. Diverse and tissue-specific mechanisms drive the health improvement. Here, we performed tissue-specific transcriptional and proteomic profiling
Autor:
Sebastian Grönke, Ilian Atanassov, Thomas Leech, Ralf Leslie Meilenbrock, Jenny Fröhlich, Jonathan Paulitz, Andreas Beyer, Luke S Tain, Matthias Mann, Nagrajuna Nagaraj, Manopriya Chokkalingam, Robert Sehlke, Linda Partridge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fbb4dc3f607d1b4dbd9a87a7eca0e68
https://doi.org/10.7554/elife.67275.sa2
https://doi.org/10.7554/elife.67275.sa2
Autor:
Paula Juricic, Yu-Xuan Lu, Thomas Leech, Lisa F. Drews, Jonathan Paulitz, Jiongming Lu, Tobias Nespital, Sina Azami, Jennifer C. Regan, Emilie Funk, Jenny Fröhlich, Sebastian Grönke, Linda Partridge
Publikováno v:
Nature aging
Juricic, P, Lu, Y X, Leech, T, Drews, L F, Paulitz, J, Lu, J, Nespital, T, Azami, S, Regan, J C, Funk, E, Fröhlich, J, Grönke, S & Partridge, L 2022, ' Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy ', Nature Aging, vol. 2, no. 9, pp. 824-836 . https://doi.org/10.1038/s43587-022-00278-w
Nature Aging
Juricic, P, Lu, Y X, Leech, T, Drews, L F, Paulitz, J, Lu, J, Nespital, T, Azami, S, Regan, J C, Funk, E, Fröhlich, J, Grönke, S & Partridge, L 2022, ' Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy ', Nature Aging, vol. 2, no. 9, pp. 824-836 . https://doi.org/10.1038/s43587-022-00278-w
Nature Aging
The licensed drug rapamycin has potential to be repurposed for geroprotection. A key challenge is to avoid adverse side effects from continuous dosing. Here we show that geroprotective effects of chronic rapamycin treatment can be obtained with a bri